BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19780256)

  • 1. Antiemetic studies on the NK1 receptor antagonist aprepitant.
    Stoutenburg JP; Raftopoulos H
    J Natl Compr Canc Netw; 2004 Sep; 2(5):491-7. PubMed ID: 19780256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting.
    Dando TM; Perry CM
    Drugs; 2004; 64(7):777-94. PubMed ID: 15025555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aprepitant--a novel NK1-receptor antagonist.
    Patel L; Lindley C
    Expert Opin Pharmacother; 2003 Dec; 4(12):2279-96. PubMed ID: 14640927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy.
    Warr D
    Expert Opin Pharmacother; 2006 Aug; 7(12):1653-8. PubMed ID: 16872268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
    J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy.
    Jordan K
    Onkologie; 2006 Feb; 29(1-2):39-43. PubMed ID: 16514255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.
    dos Santos LV; Souza FH; Brunetto AT; Sasse AD; da Silveira Nogueira Lima JP
    J Natl Cancer Inst; 2012 Sep; 104(17):1280-92. PubMed ID: 22911671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.
    Molassiotis A; Nguyen AM; Rittenberg CN; Makalinao A; Carides A
    Future Oncol; 2013 Oct; 9(10):1443-50. PubMed ID: 23987791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.
    Pendergrass K; Hargreaves R; Petty KJ; Carides AD; Evans JK; Horgan KJ
    Drugs Today (Barc); 2004 Oct; 40(10):853-63. PubMed ID: 15605119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
    Massaro AM; Lenz KL
    Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting.
    Svanberg A; Birgegård G
    Oncology; 2015; 89(1):31-6. PubMed ID: 25659986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study.
    Mir O; Durand JP; Boudou-Rouquette P; Giroux J; Coriat R; Cessot A; Ropert S; Goldwasser F; Gaillard R
    Support Care Cancer; 2012 Sep; 20(9):2235-9. PubMed ID: 22644261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aprepitant: a substance P antagonist for chemotherapy induced nausea and vomiting.
    Girish C; Manikandan S
    Indian J Cancer; 2007; 44(1):25-30. PubMed ID: 17401221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials.
    Navari RM
    Cancer Invest; 2004; 22(4):569-76. PubMed ID: 15565815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.